
Solventum Corporation
- Jurisdiction
United States - ISIN
US83444M1018 (SOLV )- Sectors
Scores
- Fair value (Benjamin Graham formula)
-
€132.36 113.5% undervalued - Financial strength (Piotroski F-Value)
-
5
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
1
/ 7
Profile
Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. Read full profile
Fundamentals
- Net revenue
€7.15B - Gross margin
54.5% - EBIT
€662.74M - EBIT margin
9.3% - Net income
€324.12M - Net margin
4.5%
Statement period: - (published )
Estimates
Fiscal Year | Net revenue | Net income |
---|---|---|
|
| |
|
| |
|
|
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
Name | Title | Transaction Date | Shares | Price | Value |
---|---|---|---|---|---|
3M CO | N/A |
|
|
|
|
Congress transactions
Name | Transaction date | Value |
---|---|---|
Julie Johnson | February 12, 2025 | $1.00K–$15.00K |
Investor transactions
Name | Shares | Value | Last change | Change type |
---|---|---|---|---|
Peter Brown |
|
|
|
Sell |
Ray Dalio |
|
|
|
Sell |